Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial

Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial

Background: Indolent systemic mastocytosis is a clonal mast cell disease that results in an increase in mast cells in the skin, bone marrow, and other organ systems. IL-6 has been shown to promote mast cell maturation, proliferation, and reactivity in vitro. Serum levels of IL-6 correlate with sever...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirsh D. Komarow, MD, Jing Wang, MS, Robin Eisch, RN, Linda Scott, CRNP, Erica H. Brittain, PhD, Dean D. Metcalfe, MD, MS
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Mastocytosis
mast cells
tryptase
anti–IL-6
sarilumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829325000992
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items